Literature DB >> 18088154

The new myth: the social value of the QALY.

Werner Brouwer, Job van Exel, Rachel Baker, Cam Donaldson.   

Abstract

Mesh：

Year:  2008        PMID： 18088154     DOI： 10.2165/00019053-200826010-00001

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN： 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  8 in total

1.  Life-cycle preferences over consumption and health: when is cost-effectiveness analysis equivalent to cost-benefit analysis?

Authors:  H Bleichrodt; J Quiggin
Journal:  J Health Econ       Date:  1999-12       Impact factor: 3.883

Review 2.  Willingness to pay for a quality-adjusted life year: in search of a standard.

Authors:  R A Hirth; M E Chernew; E Miller; A M Fendrick; W G Weissert
Journal:  Med Decis Making       Date:  2000 Jul-Sep       Impact factor: 2.583

Review 3.  Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle.

Authors:  R S Taylor; M F Drummond; G Salkeld; S D Sullivan
Journal:  BMJ       Date:  2004-10-23

4.  Incremental cost-effectiveness ratios (ICERs): the silence of the lambda.

Authors:  Amiram Gafni; Stephen Birch
Journal:  Soc Sci Med       Date:  2005-12-01       Impact factor: 4.634

5.  Can we estimate the 'social' value of a QALY? Four core issues to resolve.

Authors:  Richard D Smith; Jeff Richardson
Journal:  Health Policy       Date:  2005-01-19       Impact factor: 2.980

6.  Discounting in economic evaluations: stepping forward towards optimal decision rules.

Authors:  Hugh Gravelle; Werner Brouwer; Louis Niessen; Maarten Postma; Frans Rutten
Journal:  Health Econ       Date:  2007-03       Impact factor: 3.046

7.  Reconciliation of economic concerns and health policy: illustration of an equity adjustment procedure using proportional shortfall.

Authors:  Elly A Stolk; Gijs van Donselaar; Werner B F Brouwer; Jan J V Busschbach
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

Review 8.  Intergenerational equity: an exploration of the 'fair innings' argument.

Authors:  A Williams
Journal:  Health Econ       Date:  1997 Mar-Apr       Impact factor: 3.046
  8 in total
  11 in total

1.  The value of a QALY: individual willingness to pay for health gains under risk.

Authors:  Ana Bobinac; Job van Exel; Frans F H Rutten; Werner B F Brouwer
Journal:  Pharmacoeconomics       Date:  2014-01       Impact factor: 4.981

2.  A decision-theoretic framework for the application of cost-effectiveness analysis in regulatory processes.

Authors:  Gianluca Baio; Pierluigi Russo
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

3.  Measuring the end-of-life premium in cancer using individual ex ante willingness to pay.

Authors:  S Olofsson; U-G Gerdtham; L Hultkrantz; U Persson
Journal:  Eur J Health Econ       Date:  2017-08-12

4.  When is it too expensive? Cost-effectiveness thresholds and health care decision-making.

Authors:  Werner Brouwer; Pieter van Baal; Job van Exel; Matthijs Versteegh
Journal:  Eur J Health Econ       Date:  2019-03

5.  The social value of a QALY: raising the bar or barring the raise?

Authors:  Cam Donaldson; Rachel Baker; Helen Mason; Michael Jones-Lee; Emily Lancsar; John Wildman; Ian Bateman; Graham Loomes; Angela Robinson; Robert Sugden; Jose Luis Pinto Prades; Mandy Ryan; Phil Shackley; Richard Smith
Journal:  BMC Health Serv Res       Date:  2011-01-11       Impact factor: 2.655

6.  Cost-effectiveness analysis of non-invasive vagus nerve stimulation for the treatment of chronic cluster headache.

Authors:  James Morris; Andreas Straube; Hans-Christoph Diener; Fayyaz Ahmed; Nicholas Silver; Simon Walker; Eric Liebler; Charly Gaul
Journal:  J Headache Pain       Date:  2016-04-22       Impact factor: 7.277

Review 7.  Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries.

Authors:  Aris Angelis; Ansgar Lange; Panos Kanavos
Journal:  Eur J Health Econ       Date:  2017-03-16

8.  Estimating the willingness to pay for a quality-adjusted life year in Thailand: does the context of health gain matter?

Authors:  Montarat Thavorncharoensap; Yot Teerawattananon; Sirin Natanant; Wantanee Kulpeng; Jomkwan Yothasamut; Pitsaphun Werayingyong
Journal:  Clinicoecon Outcomes Res       Date:  2013-01-09

Review 9.  Balancing costs and benefits at different stages of medical innovation: a systematic review of Multi-criteria decision analysis (MCDA).

Authors:  Philip Wahlster; Mireille Goetghebeur; Christine Kriza; Charlotte Niederländer; Peter Kolominsky-Rabas
Journal:  BMC Health Serv Res       Date:  2015-07-09       Impact factor: 2.655

10.  Valuing QALYs in Relation to Equity Considerations Using a Discrete Choice Experiment.

Authors:  Liesbet van de Wetering; Job van Exel; Ana Bobinac; Werner B F Brouwer
Journal:  Pharmacoeconomics       Date:  2015-12       Impact factor: 4.981
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.